Rockefeller University

Oncology & Cancer

Proteome of rare liver cancer sheds new light on basic biology

Doctors have long puzzled over a mystery at the heart of fibrolamellar carcinoma, a rare and deadly liver cancer that mainly affects children and young adults. Like more common liver cancers, and liver failure itself, fibrolamellar ...

Diseases, Conditions, Syndromes

New tool to study hepatitis B could open the door to a cure

Hepatitis C and hepatitis B viruses both attack the liver, eventually causing deadly cirrhosis or cancer. But while antivirals can cure 95% of HCV infections, its cousin HBV has long eluded effective therapeutics. As a result, ...

Neuroscience

New technique captures unprecedented view of the active brain

Complex cognition and behavior, in animals and humans alike, hinges on information flowing across a network of deeply interconnected brain cells. For scientists, the scale of that network posed a major obstacle to better ...

Immunology

A unique window into 'original antigenic sin'

Our immune systems react most strongly to the viral strains we encountered in our childhoods. Scientists call this original antigenic sin (OAS)—the body's first blush with a virus like influenza or COVID being the "original ...

Immunology

How the body's B cell academy ensures a diverse immune response

Cells jostling for a spot in a germinal center face a cutthroat admissions process. Formed after exposure to a pathogen or vaccine, germinal centers act as a kind of immune system training academy, helping B cells refine ...

Medical research

When the body's B cell training grounds stay open after hours

If B cells are the munitions factories of the immune system, manufacturing antibodies to neutralize harmful pathogens, then the tiny biological structures known as germinal centers are its weapons-development facilities. ...

Immunology

How antibody therapy affects the breadth of COVID mRNA vaccines

Nearly three years into the pandemic, many of us now carry antibodies against the virus—due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment. But not all immune responses ...

page 3 from 40